BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 31922436)

  • 1. Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines.
    Gretarsson S; Nygren A; Rosendahl AH; Mylona N; Kjellén E; Jin Y; Paulsson K; Borg Å; Brun E; Tennvall J; Bergenfelz A; Greiff L; Wennerberg J; Ekblad L
    Acta Otolaryngol; 2020 Apr; 140(4):337-343. PubMed ID: 31922436
    [No Abstract]   [Full Text] [Related]  

  • 2. Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
    Pinto AT; Pojo M; Simões-Pereira J; Roque R; Saramago A; Roque L; Martins C; André S; Cabeçadas J; Leite V; Cavaco BM
    Endocrine; 2019 Nov; 66(2):288-300. PubMed ID: 31368081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
    Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
    Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
    Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of vemurafenib in anaplastic thyroid carcinoma: a case report.
    Marten KA; Gudena VK
    Cancer Biol Ther; 2015; 16(10):1430-3. PubMed ID: 26176686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
    Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer.
    Oweida A; Phan A; Vancourt B; Robin T; Hararah MK; Bhatia S; Milner D; Lennon S; Pike L; Raben D; Haugen B; Pozdeyev N; Schweppe R; Karam SD
    Thyroid; 2018 Jun; 28(6):739-747. PubMed ID: 29774792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
    Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer.
    Lang M; Longerich T; Anamaterou C
    Thyroid Res; 2023 Mar; 16(1):5. PubMed ID: 36855200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines.
    Woodward EL; Biloglav A; Ravi N; Yang M; Ekblad L; Wennerberg J; Paulsson K
    Endocr Relat Cancer; 2017 May; 24(5):209-220. PubMed ID: 28235956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation.
    Sandulache VC; Skinner HD; Wang Y; Chen Y; Dodge CT; Ow TJ; Bankson JA; Myers JN; Lai SY
    Mol Cancer Ther; 2012 Jun; 11(6):1373-80. PubMed ID: 22572813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
    Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
    Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
    Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
    J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
    Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
    Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.